(LVTX) – Hot Corp. News
-
LAVA (LVTX) Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052
-
Seagen (SGEN), LAVA Therapeutics (LVTX) Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Back to LVTX Stock Lookup
